Novo Nordisk EBITDA 2010-2024 | NVO

Novo Nordisk EBITDA for the quarter ending December 31, 2024 was $5.965B, a 38.72% increase year-over-year.

  • Novo Nordisk 2024 EBITDA was 21.38B, a 31.48% increase from 2023.
  • Novo Nordisk 2023 EBITDA was 16.261B, a 39.75% increase from 2022.
  • Novo Nordisk 2022 EBITDA was 11.635B, a 13.09% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Novo Nordisk EBITDA 2010-2024 | NVO

  • Novo Nordisk 2024 EBITDA was 21.38B, a 31.48% increase from 2023.
  • Novo Nordisk 2023 EBITDA was 16.261B, a 39.75% increase from 2022.
  • Novo Nordisk 2022 EBITDA was 11.635B, a 13.09% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$827.9B
Johnson & Johnson (JNJ)$384.4B
AbbVie (ABBV)$354.6B
Roche Holding AG (RHHBY)$262.5B
Merck (MRK)$221.8B
Novartis AG (NVS)$219.3B
Pfizer (PFE)$146.8B
Sanofi (SNY)$137.4B
Bayer (BAYRY)$22.6B
Innoviva (INVA)$1.1B